Eye Health: Bacterial Conjunctivitis Market Surges with Trends, Size, and Market Segments

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Bacterial Conjunctivitis Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The bacterial conjunctivitis market size has grown strongly in recent years. It will grow from $4.29 billion in 2023 to $4.52 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing incidence of bacterial infections, improved diagnostic capabilities, patient education and awareness programs, stringent regulatory framework, physician training and expertise..

The bacterial conjunctivitis market size is expected to see steady growth in the next few years. It will grow to $5.34 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to global population growth, rising urbanization and pollution, increased focus on preventive eye care, global health preparedness initiatives, expansion of teleophthalmology services, collaboration in research and development.. Major trends in the forecast period include innovation in drug delivery technologies, customization of treatment regimens, utilization of broad-spectrum antibiotics, introduction of adjunctive therapies, emphasis on patient education and prevention strategies..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13383&type=smp

Market Segmentation:
The bacterial conjunctivitis market covered in this report is segmented -

1) By Types: Hyperacute Bacterial Conjunctivitis, Acute Bacterial Conjunctivitis, Chronic Bacterial Conjunctivitis
2) By Drug Class: Antibiotics, Fluoroquinolones, Aminoglycosides, Macrolides, Antihistamines, Corticosteroids, Other Drug Classes
3) By Route of Administration: Oral, Topical, Other Routes Of Administrations
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

Major Driver - Rising Prevalence Of Eye Infections Drives The Bacterial Conjunctivitis Market
The increasing prevalence of eye infections is expected to propel the growth of the bacterial conjunctivitis market going forward. An eye infection is a condition in which the eye is affected by the invasion and multiplication of harmful microorganisms such as bacteria, viruses, fungi, or parasites. It includes conjunctivitis, trachoma, and keratitis. Bacterial conjunctivitis is an eye infection caused by bacteria treated with prescribed medications, self-care techniques, and hygiene measures. For instance, in October 2022, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2021, approximately 69,000 people underwent surgery for the late and blinding stage of trachoma ( Eye bacterial infection), while 64.6 million people received treatment with antibiotics for trachoma. Furthermore, in October 2022, according to The BrightFocus Foundation, a US-based nonprofit organization, there were currently 80 million glaucoma sufferers globally, and by 2040, it is projected to rise to nearly 111 million. Therefore, the increasing prevalence of eye infections is driving the growth of the bacterial conjunctivitis market.

Competitive Landscape:
Major companies operating in the bacterial conjunctivitis market report are Pfizer Inc., Johnson & Johnson, F. Hoffman La-Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Alcon, Sun Pharmaceutical Industries Ltd., Bausch + Lomb, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Hikma Pharmaceuticals, Santen Pharmaceutical Co. Ltd., Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Alembic Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Ocular Therapeutix Inc., Aldeyra Therapeutics, Nicox SA, IACTA Pharmaceuticals Inc., Cellics Therapeutics Inc.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.